Navigation Links
It's not fair! We are programmed to resist weight loss

Research confirming the human body is designed to strongly resist attempts to lose weight will be presented at an international gathering of obesity experts hosted by QUT this week.

Queensland University of Technology appetite regulation and energy balance researcher Dr Neil King, from the Institute of Health and Biomedical Innovation (IHBI), said our bodies have strong mechanisms to defend attempts to lose weight but very weak mechanisms to prevent weight gain.

Dr King's weight loss intervention studies demonstrate the "plateau effect", whereby weight loss from exercise and calorie restrictions stops at a certain point.

He conducted two studies on weight loss following induced energy deficits in two different groups of overweight and obese people.

"The "plateau effect" has been known about for some time and weight management consultants recommend longer exercise times, higher intensity or cross training to combat it," Dr King said.

"But these studies show that a plateau in body weight occurs even in the face of a continued negative energy balance."

In the first study, 30 obese men and women took part in a 12-week, laboratory-based exercise program in which they exercised five times a week.

The second study looked at weight loss in 200 males on a commercial weight loss program comprising exercise and dietary advice.

"In the first study, the subjects' energy deficit was caused by exercise only which was fixed and imposed in contrast to the second study where subjects used diet and exercise to lose weight but chose how much they did of each."

Dr King said the first group's weight loss during the first eight weeks averaged 3kg but it "plateaued" at week eight and weight loss for the next four weeks was markedly reduced (.7kg).

The second group had a variable pattern of weight loss but it, too, showed a plateau.

"There appears to be little at this stage to predict the onset
'"/>

Source:Research Australia


Page: 1 2

Related biology news :

1. Critical role in programmed cell death identified
2. Researchers unveil strategy for creating actively-programmed anti-cancer molecules
3. Heart failure: Intervention possibilities from imaging programmed cell loss
4. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
5. Enzyme allows B cells to resist death, leading to leukemia
6. NYCs First Rapid HIV Drug-resistant AIDS Case Prompts Call to Step Up HIV Prevention
7. Drug-resistant bacteria on poultry products differ by brand
8. Researchers make gains in understanding antibiotic resistance
9. MUHC scientists describe genetic resistance to rampant virus
10. Multiple-drug resistant gene expression pattern predicts treatment outcome for pediatric leukemia
11. New polysaccharide may help combat multidrug resistance in cancer
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: not fair are programmed resist weight loss

(Date:2/12/2015)... MINNETONKA, Minn. , Feb. 12, 2015 /PRNewswire/ ... technology company specializing in clinical study management systems, ... Partner Program , further distinguishing iMedNet ... for Clinical Research Organizations (CROs) and healthcare consultants.  ... sales support, prospective customer referrals and numerous co-marketing ...
(Date:2/10/2015)... 2015  Alere Inc. (NYSE: ALR), a global ... for the quarter ended December 31, 2014. ... of Alere said, "We made substantial progress in ... global leader in rapid diagnostics and delivering against ... divestiture in early January enabled us to substantially ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35
... known for a long time that some creatures evolve more ... plants. But it may be that height plays a role, ... S. National Evolutionary Synthesis Center. In a study ... Communications , Lanfear and colleagues report that shorter plants have ...
... at USC have found that a class of pharmaceuticals can ... The drugs, known as "TSPO ligands," are currently used for ... of TSPO ligand in young adult mice when pathology was ... was quite severe," said lead researcher Christian Pike of the ...
... Researchers at the University of Illinois at Chicago College of Medicine ... fat -- its main energy source -- and how changes in ... $2 million, 4-year grant from the National Heart, Lung and Blood ... for energy. These changes may play a major role in the ...
Cached Biology News:Small but speedy: Short plants live in the evolutionary fast lane 2Drugs found to both prevent and treat Alzheimer's disease in mice 2Do men's and women's hearts burn fuel differently? 2
(Date:2/27/2015)... 2015  Steep Hill, the industry leader in cannabis ... to open a full service medical cannabis quality assurance ... bringing advanced scientific tools and methodology to the state, ... is currently the only laboratory licensed by the New ... testing in order to meet the recently adopted regulatory ...
(Date:2/26/2015)... , Feb. 26, 2015 On behalf of ... affiliated companies, Wilentz, Goldman & Spitzer, P.A. ... lawsuit against Genewiz Inc. in excess of $10 million. ... GenScript,s trade secrets, and that it improperly hired one ... order denying motions for judgment notwithstanding the verdict, a ...
(Date:2/26/2015)... Feb. 26, 2015   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... 2015 goals, other key objectives, and financial guidance.  ... today at 4:30 p.m. EST to review the ... To participate in today,s call by telephone, please ...
(Date:2/26/2015)... , Feb. 26, 2015 DuPont Executive ... priorities driven by key research advancements and product launches ... today,s Bank of America Merrill Lynch 2015 Global Agriculture ... challenge of building grain supplies the last two years, ... at the pace of the last decade, when demand ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... Leaders ... www.BioConferenceLive.com , ... MA (PRWEB) -- PlatformQ , the leading producer of online events for the healthcare, ... scientific community, today announced that G. Steven Burrill, Chief Executive Officer of Burrill & Company, ...
... , VIENNA, Sept. 30 Intarcia Therapeutics, Inc. today ... of ITCA 650 (DUROS® continuous delivery of exenatide) for ... Conference of the European Association for the Study of ... substantial reductions in fasting plasma glucose (FPG) within 24 ...
... BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ) today announced that ... conference call and webcast on Wednesday, October 28, at 5:00 ... , U.S. / Canada Dial-in Number: ... Participant Code: 51404008, Replay Dial-in ...
Cached Biology Technology:CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th 2CEO of Burrill & Company to Speak at BioConference Live Slated for November 17th and 18th 3Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 2Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 3Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 4Intarcia Therapeutics, Inc. Presents Positive Results of ITCA 650 Phase 1b Study in Type 2 Diabetes at the European Association for the Study of Diabetes Conference 5BioMarin to Host Third Quarter 2009 Financial Results Conference Call and Webcast on Wednesday, October 28 at 5:00 p.m. ET 2
... Lone Wolf valve has the highest performance ... available on the market. This VSO valve ... and ensures maximum accuracy., Achieves rapid, ... and patient comfort. , Maintains ideal flow ...
Normal Hamster Serum...
...
Hamster Serum; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels; U.S. sourced, ideal for those who seek an uncompromising quality. Low Hemoglobin levels....
Biology Products: